Navigation Links
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
Date:3/9/2009

obtain an immediate supply of insulin and the ability to supply our insulin needs for the future, even if we are unable to acquire the facility itself. We are pleased with this opportunity to secure our insulin supply, which brings AFRESA one step closer to commercial readiness."

Additional information about this transaction is available in a Current Report on Form 8-K filed by MannKind with the Securities and Exchange Commission earlier today.

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscri
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
2. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
5. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
6. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
7. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
8. MannKind to Present at the UBS Global Life Sciences Conference
9. MannKind Corporation Reports Second Quarter Financial Results
10. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
11. MannKind to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma Inc. ... recommended approach for protecting personal data in Clinical ... patients and others. The document describes an approach ... from CSRs and other related clinical trial documents, ... The goal of the TransCelerate CSR Redaction approach ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Opertech ... new highly efficient, cost effective approach to sensory ... No. 8,820,265 by the U.S. Patent and Trademark ... Opertech. , “Opertech’s taste evaluation technology ... first automated high throughput system for rapid characterization ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... , CAMBRIDGE, Mass., Aug. 11 Tolerx, ... therapies for immune-mediated diseases, today announced changes to the protocol for its ... of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune ... urable Response Therapy E valuation F or E arly ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of the world,s ... that the entry and uptake of premium-priced biologics will drive the ... $420 million in 2008 to nearly $2 billion in 2018. , ... Lupus Erythematosus finds that the primary drivers of market growth ...
... , , ... that BD Biosciences, a segment of BD (Becton, Dickinson and ... Pathway Navigation technologies into its new website. By leveraging ... its research customers to quickly and easily identify products and ...
Cached Biology Technology:Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 2
(Date:9/2/2014)... (September 2, 2014) In the battle between our ... unknown ally in bacteria-killing viruses known as phages. In ... Hospital, Partners In Health, Haiti,s National Public Health Laboratory, ... to give up their virulence in order to survive. ... found that cholera,s mutational escape from phage predation ...
(Date:9/2/2014)... also known as perching birds, that migrate by night ... in autumn to reach their destinations. This seasonal difference ... only make short migratory flights, says researcher Cecilia Nilsson ... Behavioral Ecology and Sociobiology . , Nilsson, in ... tracking radar to measure over three years the speed ...
(Date:9/2/2014)... What,s the price of your integrity? Tell the truth; everyone ... but at some point, we,ll lie if the benefit is ... brain in which we make that decision. , The ... Neuroscience . , "We prefer to be honest, even ... author and a postdoctoral associate at the Virginia Tech ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Migrating birds sprint in spring, but take things easy in autumn 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4
... proteins are the bad guys that help bacterial pathogens do ... immune system. In essence, they knock down the front ... Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
... could soon be roaming our pastures, reports Cath O’Driscoll in ... in New Zealand have discovered that some cows have genes ... and plan to use this information to breed herds of ... plan to breed commercial herds producing milk with the unique ...
... H5N1 strain of avian influenza may hold the key to ... of researchers. In a study published today in the open ... antibodies taken from avian flu survivors in Vietnam can be ... virus in culture vitro and in mice. , The H5N1 ...
Cached Biology News:How plague-causing bacteria disarm host defense 2Skimmed milk -- Straight from the cow 2Avian influenza survivors' antibodies effective at neutralising H5N1 strain 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: